Key takeaways
Emtricitabine (Emtriva) and tenofovir disoproxil fumarate (Viread) are both antiretroviral (ARV) medications used to treat HIV. They belong to the same class of medications called nucleoside reverse transcriptase inhibitors (NRTIs), which work by preventing the virus from making copies of itself. While both medications are used for HIV treatment in combination with other HIV medications, tenofovir disoproxil fumarate (Viread) is also FDA-approved for treating chronic hepatitis B virus (HBV) infection, making it more versatile. Emtricitabine (Emtriva) is available as a capsule and oral solution, while tenofovir disoproxil fumarate (Viread) comes in tablet and powder forms. Both medications are taken once daily, but emtricitabine (Emtriva) requires dose adjustments for kidney problems, whereas tenofovir disoproxil fumarate (Viread) can cause bone and kidney issues. Common side effects of emtricitabine (Emtriva) include nausea and fatigue, while tenofovir disoproxil fumarate (Viread) may cause diarrhea and headaches. Additionally, tenofovir disoproxil fumarate (Viread) has more drug interactions, especially with medications for hepatitis C and HIV.
